PortalPublikationenUpregulation of SPDEF is associated with poor prognosis in p...

Upregulation of SPDEF is associated with poor prognosis in prostate cancer

Standard

Upregulation of SPDEF is associated with poor prognosis in prostate cancer. / Meiners, Jan; Schulz, Katharina; Möller, Katharina; Höflmayer, Doris; Burdelski, Christoph; Hube-Magg, Claudia; Simon, Ronald; Göbel, Cosima; Hinsch, Andrea; Reiswich, Viktor; Weidemann, Sören; Izbicki, Jacob R; Sauter, Guido; Jacobsen, Frank; Möller-Koop, Christina; Mandelkow, Tim; Blessin, Niclas C; Lutz, Florian; Viehweger, Florian; Lennartz, Maximillian; Fraune, Christoph; Heinzer, Hans; Minner, Sarah; Bonk, Sarah; Huland, Hartwig; Graefen, Markus; Schlomm, Thorsten; Büscheck, Franziska.

in: ONCOL LETT, Jahrgang 18, Nr. 5, 11.2019, S. 5107-5118.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Meiners, J, Schulz, K, Möller, K, Höflmayer, D, Burdelski, C, Hube-Magg, C, Simon, R, Göbel, C, Hinsch, A, Reiswich, V, Weidemann, S, Izbicki, JR, Sauter, G, Jacobsen, F, Möller-Koop, C, Mandelkow, T, Blessin, NC, Lutz, F, Viehweger, F, Lennartz, M, Fraune, C, Heinzer, H, Minner, S, Bonk, S, Huland, H, Graefen, M, Schlomm, T & Büscheck, F 2019, 'Upregulation of SPDEF is associated with poor prognosis in prostate cancer', ONCOL LETT, Jg. 18, Nr. 5, S. 5107-5118. https://doi.org/10.3892/ol.2019.10885

APA

Meiners, J., Schulz, K., Möller, K., Höflmayer, D., Burdelski, C., Hube-Magg, C., Simon, R., Göbel, C., Hinsch, A., Reiswich, V., Weidemann, S., Izbicki, J. R., Sauter, G., Jacobsen, F., Möller-Koop, C., Mandelkow, T., Blessin, N. C., Lutz, F., Viehweger, F., ... Büscheck, F. (2019). Upregulation of SPDEF is associated with poor prognosis in prostate cancer. ONCOL LETT, 18(5), 5107-5118. https://doi.org/10.3892/ol.2019.10885

Vancouver

Meiners J, Schulz K, Möller K, Höflmayer D, Burdelski C, Hube-Magg C et al. Upregulation of SPDEF is associated with poor prognosis in prostate cancer. ONCOL LETT. 2019 Nov;18(5):5107-5118. https://doi.org/10.3892/ol.2019.10885

Bibtex

@article{8629b47d419047778ec4a6d8ccba57e7,
title = "Upregulation of SPDEF is associated with poor prognosis in prostate cancer",
abstract = "SAM pointed domain-containing Ets transcription factor (SPDEF), a member of the ETS transcription factor family, has been associated with prostate cancer development; however, its role in tumour development and progression is controversial. In the present study, SPDEF expression was analysed on a tissue microarray with >12,000 prostate cancer samples. SPDEF expression levels were higher in most prostate cancer samples than in normal prostate epithelium, suggesting SPDEF was upregulated in cancer. Nuclear SPDEF expression was identified in 80% of prostate cancer samples, and considered weak in 26.4%, moderate in 40.1% and strong in 13.5% of cases. SPDEF positivity was significantly associated with tumour stage, Gleason grade, lymph node metastasis and PSA recurrence (all P<0.0001). SPDEF overexpression was more common in ERG positive (94%) than in ERG negative cancer (69%; P<0.0001). Elevated SPDEF expression predicted poor prognosis independent from established prognostic parameters, including Gleason grade, pT, pN, serum PSA level and nodal status (P<0.01). In summary, SPDEF overexpression was associated with aggressive behaviour, particularly in ERG negative prostate cancer, and may have potential for clinical application.",
author = "Jan Meiners and Katharina Schulz and Katharina M{\"o}ller and Doris H{\"o}flmayer and Christoph Burdelski and Claudia Hube-Magg and Ronald Simon and Cosima G{\"o}bel and Andrea Hinsch and Viktor Reiswich and S{\"o}ren Weidemann and Izbicki, {Jacob R} and Guido Sauter and Frank Jacobsen and Christina M{\"o}ller-Koop and Tim Mandelkow and Blessin, {Niclas C} and Florian Lutz and Florian Viehweger and Maximillian Lennartz and Christoph Fraune and Hans Heinzer and Sarah Minner and Sarah Bonk and Hartwig Huland and Markus Graefen and Thorsten Schlomm and Franziska B{\"u}scheck",
note = "Copyright: {\textcopyright} Meiners et al.",
year = "2019",
month = nov,
doi = "10.3892/ol.2019.10885",
language = "English",
volume = "18",
pages = "5107--5118",
journal = "ONCOL LETT",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "5",

}

RIS

TY - JOUR

T1 - Upregulation of SPDEF is associated with poor prognosis in prostate cancer

AU - Meiners, Jan

AU - Schulz, Katharina

AU - Möller, Katharina

AU - Höflmayer, Doris

AU - Burdelski, Christoph

AU - Hube-Magg, Claudia

AU - Simon, Ronald

AU - Göbel, Cosima

AU - Hinsch, Andrea

AU - Reiswich, Viktor

AU - Weidemann, Sören

AU - Izbicki, Jacob R

AU - Sauter, Guido

AU - Jacobsen, Frank

AU - Möller-Koop, Christina

AU - Mandelkow, Tim

AU - Blessin, Niclas C

AU - Lutz, Florian

AU - Viehweger, Florian

AU - Lennartz, Maximillian

AU - Fraune, Christoph

AU - Heinzer, Hans

AU - Minner, Sarah

AU - Bonk, Sarah

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Schlomm, Thorsten

AU - Büscheck, Franziska

N1 - Copyright: © Meiners et al.

PY - 2019/11

Y1 - 2019/11

N2 - SAM pointed domain-containing Ets transcription factor (SPDEF), a member of the ETS transcription factor family, has been associated with prostate cancer development; however, its role in tumour development and progression is controversial. In the present study, SPDEF expression was analysed on a tissue microarray with >12,000 prostate cancer samples. SPDEF expression levels were higher in most prostate cancer samples than in normal prostate epithelium, suggesting SPDEF was upregulated in cancer. Nuclear SPDEF expression was identified in 80% of prostate cancer samples, and considered weak in 26.4%, moderate in 40.1% and strong in 13.5% of cases. SPDEF positivity was significantly associated with tumour stage, Gleason grade, lymph node metastasis and PSA recurrence (all P<0.0001). SPDEF overexpression was more common in ERG positive (94%) than in ERG negative cancer (69%; P<0.0001). Elevated SPDEF expression predicted poor prognosis independent from established prognostic parameters, including Gleason grade, pT, pN, serum PSA level and nodal status (P<0.01). In summary, SPDEF overexpression was associated with aggressive behaviour, particularly in ERG negative prostate cancer, and may have potential for clinical application.

AB - SAM pointed domain-containing Ets transcription factor (SPDEF), a member of the ETS transcription factor family, has been associated with prostate cancer development; however, its role in tumour development and progression is controversial. In the present study, SPDEF expression was analysed on a tissue microarray with >12,000 prostate cancer samples. SPDEF expression levels were higher in most prostate cancer samples than in normal prostate epithelium, suggesting SPDEF was upregulated in cancer. Nuclear SPDEF expression was identified in 80% of prostate cancer samples, and considered weak in 26.4%, moderate in 40.1% and strong in 13.5% of cases. SPDEF positivity was significantly associated with tumour stage, Gleason grade, lymph node metastasis and PSA recurrence (all P<0.0001). SPDEF overexpression was more common in ERG positive (94%) than in ERG negative cancer (69%; P<0.0001). Elevated SPDEF expression predicted poor prognosis independent from established prognostic parameters, including Gleason grade, pT, pN, serum PSA level and nodal status (P<0.01). In summary, SPDEF overexpression was associated with aggressive behaviour, particularly in ERG negative prostate cancer, and may have potential for clinical application.

U2 - 10.3892/ol.2019.10885

DO - 10.3892/ol.2019.10885

M3 - SCORING: Journal article

C2 - 31612022

VL - 18

SP - 5107

EP - 5118

JO - ONCOL LETT

JF - ONCOL LETT

SN - 1792-1074

IS - 5

ER -